Biotechnology

YD Bio

YD Bio released FY2024 Q4 earnings on April 30 (EST), actual revenue USD 142.69 K, actual EPS USD -0.5483

YD Bio released FY2024 9 Months earnings on April 30 (EST), actual revenue USD 415.42 K, actual EPS USD -0.7793

YD Bio released FY2024 Annual Earnings on April 30, 2025 (EST), with actual revenue of USD 510.36K and EPS of USD -1.2901

YD Bio released FY2024 Q3 earnings on April 30 (EST), actual revenue USD 142.69 K, actual EPS USD -0.5483

YD Bio released FY2023 9 Months Earnings on March 17 Post-Market (EST), actual revenue USD 289.99K, actual EPS USD 0.0055

YD Bio released FY2022 Annual Earnings on March 17 (EST), Actual Revenue: USD 12.07 K, Actual EPS: USD 0

YD Bio released FY2023 Q4 earnings on March 17, 2025 (EST) with actual revenue of USD 72.94 K and EPS of USD 0.0055

YD Bio released FY2023 earnings on March 17 (EST), actual revenue USD 350.13K, actual EPS USD 0.0128

YD Bio released FY2023 Q3 earnings on March 17, 2025 (EST), with actual revenue of USD 72.94 K and EPS of USD 0.0055

YD Bio released FY2024 Q1 earnings on November 25, 2024 (EST) with actual revenue of USD 112.49 K and EPS of USD -0.08

YD Bio released FY2024 Q2 earnings on November 25 (EST), actual revenue USD 160.24K, actual EPS USD -0.1509

YD Bio released FY2023 Q2 earnings on November 25 (EST), actual revenue USD 114.93K, actual EPS USD 0

YD Bio released FY2023 Q1 earnings on November 25 (EST), actual revenue USD 102.13K, actual EPS USD 0

YD Bio released FY2023 Semi-Annual Earnings on November 25 (EST), actual revenue USD 204.26 K, actual EPS USD 0

Earnings report released on November 25, 2024 (BJT) with actual revenue of USD 224.98 K and actual EPS of USD -0.16

Aditxt

LINKERS INDUSTRIES LIMITED

Freecast

Butterfly Network

CDT Equity

Asia Pacific Wire & Cable

Agape ATP

Bimergen Energy

Horizon Quantum

Defiance Daily Target 2X Long VELO ETF

YDES

HITI

PRFX

CRVO

IMCC

CUPR

CAMP

SCLX

EWTX

In Tuesday's pre-market session, several healthcare stocks saw significant movement. Gainers included CervoMed (+24.2%), IM Cannabis (+18.77%), and High Tide (+14.22%). Camp4 Therapeutics rose 13.63% following its Q2 earnings report. Conversely, losers featured PRF Technologies (-30.1%), Cuprina Holdings (-27.35%), and Scilex Holding (-21.39%). Edgewise Therapeutics and YD Bio also declined over 14%. Market caps ranged from $2.1 million to $3.7 billion.

benzinga_article

High Tide

PRF Tech

CervoMed

IM Cannabis

Cuprina

CAMP4 Therapeutics

Scilex

Edgewise Therapeutics

Hyperliquid Strategies

Lunai Bioworks

SANUWAVE Health

YD BIO LTD C/WTS 28/08/2030(TO PUR COM)

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

YD Bio fell 14.13%; AbbVie rose 2.85%, with a transaction volume of USD 882 million; Gilead Sciences rose 0.40%, with a transaction volume of USD 613 million; Amgen rose 2.05%, with a transaction volume of USD 591 million; Vertex Pharmaceuticals rose 4.27%, with a market value of USD 113.4 billion

Price Alert

Abbvie

Gilead Sciences

Amgen

Vertex Pharma

U.S. stock market midday update: YD Bio down 14.13% with increased volume and sharp decline, no major negative news, intensified capital speculation causing volatility

FCEL

YD Bio pre-market up 10.53%; FuelCell Energy pre-market down 7.89%; Solidion Tech pre-market up 212.10%; CXApp pre-market up 81.28%; Splash Beverage pre-market up 65.62%

FuelCell Energy

Solidion Tech

CXApp

Splash Beverage

Pre-market hot trades in US stocks: YD Bio up 10.53% in pre-market; FuelCell Energy down 7.89% in pre-market

SBIO

LABU

IBBQ

YD Bio Limited Reports Full Year 2025 Financial Results | YDES Stock News

StockTitan

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

YD Bio Limited Reports Full Year 2025 Financial Results | YDES Stock News

ULVR

Unilever plc (UL) shares have entered oversold territory with a Relative Strength Index (RSI) of 29.5, indicating potential buying opportunities as heavy selling may be exhausting. The stock traded as low as $57.18, with a 52-week range of $54.95 to $74.975. In contrast, the S&P 500 ETF (SPY) has an RSI of 68.3. Investors may consider this RSI reading as a signal to look for entry points in UL shares.

- Warren Buffett suggests being fearful when others are greedy and greedy when others are fearful, a principle that can be illustrated using the Relative Strength Index (RSI).  
- Unilever plc (Symbol: UL) saw its RSI drop to 29.5, indicating it is in oversold territory, while the S&P 500 ETF (SPY) has an RSI of 68.3.  
- This oversold condition may present bullish investors with potential buying opportunities as selling pressure appears to be exhausting.

nasdaq

Unilever

Unilever PLC

SPDR S&P 500

Nasdaq

Oversold Conditions For Unilever (UL)

RDGT

ANNA

Overview of the US Stock Market The current market shows a clear trend of differentiation, with technology stocks and the biopharmaceutical sector performing particularly well. Stocks with significant gains are mainly concentrated in innovative companies and emerging technology fields, with funds seemingly favoring high-growth stocks. Meanwhile, some traditional industries and small-cap stocks have faced considerable selling pressure, leading to increased overall volatility and a rise in short-term trading activity. The sharp decline of Ridgetech (down 90.50%) in the last hour has attracted widespread attention in the market, with trading volume significantly increasing and investor sentiment becoming tense. The stock's dramatic fluctuations appear to be related to recent financial issues, prompting a rapid withdrawal of funds. Strong stocks: 1. Fundrise Innovation Fund LLC: up 51.09%, with a six-month gain of 270.27%, continuously attracting capital inflows and boosting market sentiment. 2. AleAnna: up 46.65%, reaching a new 60-day high, with active short-term funds and optimistic market outlook. 3. Swarmer: up 44.15%, with increased trading volume indicating strong buying interest. 4. Sol-Gel Tech: up 41.24%, with a six-month gain of 215.83%, as investors are excited about its product line expansion. 5. YD Bio: up 34.67%, with significantly increased trading volume, as the market shows interest in its new drug development progress

Ridgetech

Fundrise Innovation Fund LLC

AleAnna

Swarmer

Sol-Gel Tech

Yimutian

Merlin

Novabay Pharmac

Quantum Biopharma

Southland

Hitek Global Inc.

Jianzhi Edu Tech

Ryde

Erayak Power Solution

ImmunityBio

Stablecoin Development

U.S. Stock Market Movement Update: The U.S. stock market experienced significant volatility, with Ridgetech plummeting 90.50% and Fundrise Innovation Fund soaring 51.09%

TSEM

NCLH

ARKG

U.S. stocks fell, with the Nasdaq dropping 200 points. However, Apogee Therapeutics saw a significant rise of 19.4% after positive trial data for its anti-IL-13 antibody. Other notable gainers included Satellogic (+20.6%), YD Bio (+17.4%), and AXT Inc (+15.6%). Tower Semiconductor rose 8.9% following a breakthrough in data transmission technology. Norwegian Cruise Line gained 8% due to lower oil costs after geopolitical developments.

- U.S. stocks declined, with the Nasdaq Composite dropping approximately 200 points.  
- Apogee Therapeutics Inc shares rose 19.4% to $78.89 after announcing positive Phase 2 APEX trial data for its drug zumilokibart.  
- Several other stocks experienced significant gains, including Satellogic Inc with a 20.6% increase and Norwegian Cruise Line, which rose 8% due to falling oil prices.

Tower Semicon

Norwegian Cruise

Apogee Therapeutic

Satellogic

iShares US Medical Devices

MicroSectors™ Travel 3X Leveraged ETNs

AdvisorShares Hotel ETF

Proshares UltraPro QQQ

Invesco Leisure & ENT ETF

Ark Innovation ETF

Ark Genomic Revolution ETF

Invesco QQQ Trust

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday

YD Bio (NASDAQ:YDES) shares rose 7.9% to $7.8770 during mid-day trading, despite a significant drop in trading volume. Analyst ratings show a mixed outlook, with Wall Street Zen upgrading the stock to a 'hold' while Weiss Ratings maintains a 'sell' rating. Institutional investor Geode Capital Management increased its stake by 10%. The stock's 50-day moving average is $10.26, and it currently holds an average rating of 'sell' among analysts. Investors are advised to consider other stocks recommended by top analysts instead of YD Bio.

Market Beat

Direxion S&P Biotech Bear 3X

YD Bio (NASDAQ:YDES) Trading 7.9% Higher   - Still a Buy?

NTLA

This week's biotech news highlights significant FDA approvals and clinical developments. Intellia Therapeutics received FDA clearance to resume its MAGNITUDE-2 Phase 3 trial for ATTRv-PN, while Outset Medical's Tablo Hemodialysis System gained 510(k) clearance. OKYO Pharma's Urcosimod trial design was endorsed by the FDA, but REGENXBIO faced clinical holds on its gene therapy programs. Almirall's Seysara was approved in China for acne treatment, and YD Bio signed a letter of intent to acquire Safe Save Medical for $26.87 million.

rttnews

Intellia Therap

iShares Genomics Immunology and Healthcare ETF

Franklin Genomic Adv ETF

OKYO Pharma

Regenxbio

Wisdomtree BioRevolution Fund ETF

CRISPR Therap

Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE

YD Bio(YDES.US)

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stock market midday update: YD Bio down 14.13% with increased volume and sharp decline, no major negative news, intensified capital speculation causing volatility

Pre-market hot trades in US stocks: YD Bio up 10.53% in pre-market; FuelCell Energy down 7.89% in pre-market

YD Bio Limited Reports Full Year 2025 Financial Results | YDES Stock News

Oversold Conditions For Unilever (UL)

U.S. Stock Market Movement Update: The U.S. stock market experienced significant volatility, with Ridgetech plummeting 90.50% and Fundrise Innovation Fund soaring 51.09%

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday

YD Bio (NASDAQ:YDES) Trading 7.9% Higher - Still a Buy?

Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE